GuidelineEuropean journal of nuclear medicine and molecular imaging2010
EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.
Guideline in European journal of nuclear medicine and molecular imaging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03468582 (Pilot Study Using 123I Radiolabeled 3BNC117 SPECT/CT to Image HIV Reservoir in Chronically Infected HIV Patients), which is not on this map. Cited by 148 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Study Using 123I Radiolabeled 3BNC117 SPECT/CT to Image HIV Reservoir in Chronically Infected HIV Patients
Who cites it
148 citing papers in PubMed.
- Tumor and Organ Dose Estimates fromJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Dosimetry of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Dosimetry and pharmacokinetics of [European journal of nuclear medicine and molecular imaging · 2024Trial
- A phase I/II study of the safety and efficacy of [European journal of nuclear medicine and molecular imaging · 2023Trial
- Evaluation of Safety and Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Radiation Dosimetry inJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Trial
- Cholecystokinin 2 Receptor AgonistJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Trial
- Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.European journal of nuclear medicine and molecular imaging · 2014Trial
- Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.European journal of nuclear medicine and molecular imaging · 2012Trial
- Cancer theranostics.Nature reviews. Cancer · 2026Review
- Dose-activity relationship in [Annals of nuclear medicine · 2026Article
- Biodistribution and dosimetry of the carbon-11 labelled PARP1-selective PET radiopharmaceutical [EJNMMI research · 2026Article
- DNA damage induction and repair in peripheral blood mononuclear cells induced by internal ex vivo irradiation with β- and γ-emitting radionuclides.Zeitschrift fur medizinische Physik · 2026Article
- State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.Zeitschrift fur medizinische Physik · 2026Review
- Radiation induced lymphopenia during PRRT: Incidence, course, predictive factors, and association with overall survival.European journal of nuclear medicine and molecular imaging · 2026Article
- Design and validation of a deep learning GAN for predictingJournal of applied clinical medical physics · 2026Article
- Multiple vertebrae improves precision in image-based bone marrow absorbed dose estimation in [EJNMMI physics · 2026Article
- Dosimetry of [EJNMMI research · 2026Article
- Recent advances and current landscape of software tools for image analysis and dosimetry in nuclear medicine.EJNMMI physics · 2026Review
- Safety and efficacy ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
88 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe level of administered activity in radionuclide therapy is often limited by haematological toxicity resulting from the absorbed dose delivered to the bone marrow. The purpose of these EANM guidelines is to provide advice to scientists and clinicians on data acquisition and data analysis related to bone-marrow and whole-body dosimetry. MATERIALS AND
methodsThe guidelines are divided into sections "Data acquisition" and "Data analysis". The Data acquisition section provides advice on the measurements required for accurate dosimetry including blood samples, quantitative imaging and/or whole-body measurements with a single probe. Issues specific to given radiopharmaceuticals are considered. The Data analysis section provides advice on the calculation of absorbed doses to the whole body and the bone marrow. The total absorbed dose to the bone marrow consists of contributions from activity in the bone marrow itself (self-absorbed dose) and the cross-absorbed dose to the bone marrow from activity in bone, larger organs and the remainder of the body.
conclusionAs radionuclide therapy enters an era where patient-specific dosimetry is used to guide treatments, accurate bone-marrow and whole-body dosimetry will become an essential element of treatment planning. We hope that these guidelines will provide a basis for the optimization and standardization of the treatment of cancer with radiopharmaceuticals, which will facilitate single- and multi-centre radionuclide therapy studies.
Indexed as
Identifiers
20411259What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.